KDOQI (Kidney Disease Outcomes Quality Initiative)
NKF KDOQI GUIDELINES

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease


Figures

Figure 1.

Kidney Failure in the United States
Figure 2. Relationship Between Current and Previous Anemia Guidelines
Figure 3. Relationship Between Hb Level and eGFR
Figure 4. Relationship Between eGFR and Prevalence of Anemia as Defined by Differing Hb Levels for (A) Males and (B) Females
Figure 5. Prevalence of Anemia by CKD Stage
Figure 6. Relationship Between Level of Renal Function, Reflected by SCr Level or GFR, and Prevalence of Anemia, Defined at Different Hb Cutoff Levels, Among Patients under the Care of Physicians
Figure 7. Hb Percentiles by GFR in the Canadian Multicentre Longitudinal Cohort Study
Figure 8. Prevalence of Low Hb Level by Category of GFR in the Canadian Multicentre Longitudinal Cohort Study
Figure 9. Prevalence of Low Hb Level by eGFR in Patients with Diabetics Compared with the General Population
Figure 10. Changes in Hb Levels and eGFR Over 2 years in Adult Patients with CKD Stages 3 and 4 Not Treated with ESA
Figure 11. Distribution of Hb Levels in Adult Males and Females by Age Group
Figure 12. Distribution of Ferritin and TSAT Values by Age Group in Males and Females
Figure 13. Distribution of Hb Levels by Ferritin Range in Patients with CKD
Figure 14. Distribution of Hb Levels by TSAT Range in Patients with CKD
Figure 15. Target and Achieved Hb Levels in 18 RCTs Comparing Higher Against Lower (or Placebo/Control) Hb Targets for ESA Therapy
Figure 16. Baseline Mean Pretreatment Hb Levels Compared with Achieved Mean Hb Levels in the Upper and Lower Target
Figure 17. Exposure to Eprex® and Case Counts of PRCA
Figure 18. Mean Epoetin Dose per Patient per Administration by Percentile of Dose (1st, 5th to 95th, and 99th)
Figure 19. Process of Triaging a Topic to a Systematic Review or a Narrative Review